IFW

CASE LA0093 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Lisa Swidra	Lisa Swidra	5/19/04
Type or print name	Signature	Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

SHER ET AL.

APPLICATION NO: 10/712,823

FILED: NOVEMBER 13, 2003

FOR: TRIGLYCERIDE AND TRIGLYCERIDE-LIKE PRODRUGS OF GLYCOGEN PHOSPHORYLASE INHIBITING COMPOUNDS

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3816

Jonathan N. Provoost
Attorney for Applicants
Reg. No. 44,292

Date: May 19, 2004

FORM PTO-1449 (REV. 7-85)
U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
LA0093 NP
APPLICATION NO.
10/712,823
APPLICANT
SHER ET AL.
FILING DATE
NOVEMBER 13, 2003
Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	3,674,836	7/4/72	Creger			
	AB	3,983,140	9/28/76	Endo et al.			
	AC	4,027,009	5/31/77	Grier et al.			
	AD	4,231,938	11/4/80	Monaghan et al.			
	AE	4,346,227	8/24/82	Terahara et al.			
	AF	4,448,784	5/15/84	Glamkowski et al.			
	AG	4,450,171	5/22/84	Hoffman et al.			
	AH	4,499,289	2/12/85	Baran et al.			
	AI	4,512,988	4/23/85	Weller, III et al.			
	AJ	4,613,610	9/23/86	Wareing			
	AK	4,647,576	3/3/87	Hoefle et al.			
	AL	4,681,893	7/21/87	Roth			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	AM	EP 0 107 095	9/9/87	EP			☐	☐
	AN	EP 0 142 146	8/31/88	EP			☐	☐
	AO	EP 0 160 546	11/6/85	EP			☐	☐
	AP	EP 0 221 025	5/6/87	EP			☐	☐
	AQ	EP 0 416 740	3/13/91	EP			☐	☐

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Albright, J.D. et al., "Synthesis of 1,4,5,6-Tetrahydropyrazolo[3,4-*d*]pyrido[3,2-*b*]azepine", J. Heterocyclic Chem., Vol. 37, pp. 41-46 (2000)
	AS	Aranyos, A. et al., "Novel Electron-Rich Bulky Phosphine Ligands Facilitate the Palladium-Catalyzed Preparation of Diaryl Ethers", J. Am. Chem. Soc., Vol. 121, No. 18, pp. 4369-4378 (1999)
	AT	Arbeeny, C. et al., "The Metabolic Syndrome: From Pathophysiology to Novel Treatment Strategies", Curr. Med. Chem. - Imm., Endoc. & Metab Agents., Vol. 1, No. 1, pp. 1-24 (2001)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
LA0093 NP
APPLICATION NO.
10/712,823
APPLICANT
SHER ET AL.
FILING DATE
NOVEMBER 13, 2003
Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	2AA	4,686,237	8/11/87	Anderson			
	2AB	4,692,522	9/8/87	Parsons et al.			
	2AC	4,755,509	7/5/88	Teulon			
	2AD	4,871,721	10/3/89	Biller			
	2AE	4,924,024	5/8/90	Biller			
	2AF	5,006,530	4/9/91	Angerbauer et al.			
	2AG	5,011,930	4/30/91	Fujikawa et al.			
	2AH	5,177,080	1/5/93	Angerbauer et al.			
	2AI	5,206,235	4/27/93	Fisher et al.			
	2AJ	5,260,440	11/9/93	Hirai et al.			
	2AK	5,273,995	12/28/93	Roth			
	2AL	5,354,772	10/11/94	Kathawala			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	2AM	EP 0 978 279	2/9/00	EP			☐	☐
	2AN	EP 1 088 824	1/7/04	EP			☐	☐
	2AO	2 596 393	10/2/87	FR			☐	☐
	2AP	JP 2000-256318	9/19/00	JP			☐	☐
	2AQ	GB 2 205 837	12/21/88	UK			☐	☐

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	2AR	Armstrong, III, J.D. et al., "An Efficient Asymmetric Synthesis of (R)-3-Amino-2,3,4,5-tetrahydro-1H-[1]benzazepin-2-one", Tetrahedron Letters, Vol. 35, No. 20, pp. 3239-3242 (1994)
	2AS	Ashworth, D.M. et al., "2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV", Bioorganic & Medicinial Chemistry Letters, Vol. 6, No. 10, pp. 1163-1166 (1996)
	2AT	Ashworth, D.M. et al., "4-Cyanothiazolidides as Very Potent, Stable Inhibitors of Dipeptidyl Peptidase IV", Bioorganic & Medicinial Chemistry Letters, Vol. 6, No. 22, pp. 2745-2748 (1996)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
LA0093 NP
APPLICATION NO.
10/712,823
APPLICANT
SHER ET AL.
FILING DATE
NOVEMBER 13, 2003
Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	3AA	5,385,929	1/31/95	Bjorge et al.			
	3AB	5,488,064	1/30/96	Sher			
	3AC	5,491,134	2/13/96	Sher et al.			
	3AD	5,506,219	4/9/96	Robl			
	3AE	5,541,204	7/30/96	Sher et al.			
	3AF	5,545,735	8/13/96	Bochis et al.			
	3AG	5,552,397	9/3/96	Karanewsky et al.			
	3AH	5,594,006	1/14/97	Sakamoto et al.			
	3AI	5,595,872	1/21/97	Wetterau, II et al.			
	3AJ	5,612,359	3/18/97	Murugesan			
	3AK	5,614,492	3/25/97	Habener			
	3AL	5,652,363	7/29/97	Khanna et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	3AM	WO 86/03488	6/19/86	PCT			☐	☐
	3AN	WO 86/07054	12/4/86	PCT			☐	☐
	3AO	WO 93/14067	7/22/93	PCT			☐	☐
	3AP	WO 96/36596	11/21/96	PCT			☐	☐
	3AQ	WO 96/38144	12/5/96	PCT			☐	☐

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	3AR	Ball, J.B. et al., "Synthesis and Conformational Analyses of Some 3-Amino-2,5-dioxo-2,3,4,5-tetrahydro-1*H*-1-benzazepine Derivatives: X-Ray Crystal Structure of 3*S*-3-[[(1,1-Dimethylethoxy)carbonyl]amino]-2,5-dioxo-2,3,4,5-tetrahydro-1*H*-1-benzazepine", J. Heterocyclic Chem. Vol. 27, pp. 279-286 (1990)
	3AS	Bebernitz, G.R. et al., "Reduction in Glucose Levels in STZ Diabetic Rats by 4-(2,2-Dimethyl-1-oxopropyl)benzoic Acid: A Prodrug Approach for Targeting the Liver", J. Med. Chem. Vol. 44, No. 4, pp. 512-523 (2001)
	3AT	Bell, I.M. et al., "Development of Orally Active Oxytocin Antagonists: Studies on 1-(1-{4-[1-(2-Methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2-methoxybenzoyl}piperidin-4-yl)-1,4-dihydrobenz[*d*][1,3]oxazin-2-one (L-372,662) and Related Pyridines", J. Med. Chem., Vol. 41, No. 12, pp. 2146-2163 (1998)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
LA0093 NP
APPLICATION NO.
10/712,823
APPLICANT
SHER ET AL.
FILING DATE
NOVEMBER 13, 2003

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	4AA	5,686,104	11/11/97	Mills et al.			
	4AB	5,691,322	11/25/97	Robl			
	4AC	5,712,279	1/27/98	Biller et al.			
	4AD	5,712,396	1/27/98	Magnin et al.			
	4AE	5,719,278	2/17/98	Albright et al.			
	4AF	5,739,135	4/14/98	Biller et al.			
	4AG	5,753,675	5/19/98	Wattanasin			
	4AH	5,760,246	6/2/98	Biller et al.			
	4AI	5,770,615	6/23/98	Cheng et al.			
	4AJ	5,776,983	7/7/98	Washburn et al.			
	4AK	5,789,587	8/4/98	Fisher et al.			
	4AL	5,827,875	10/27/98	Dickson, Jr. et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	4AM	WO 96/39384	12/12/96	PCT			☐	☐
	4AN	WO 96/39385	12/12/96	PCT			☐	☐
	4AO	WO 97/12613	4/10/97	PCT			☐	☐
	4AP	WO 97/12615	4/10/97	PCT			☐	☐
	4AQ	WO 97/21993	6/19/97	PCT			☐	☐

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	4AR	Berg-Nielsen, K. et al., "Amino-Claisen Rearrangement of Vinyl Propargylamines and Pyrindane Synthesis from a Divinyl Ketone", Acta Chemica Scandinavica B, Vol. 32, pp. 553-556 (1978)
	4AS	Biller, S.A. et al., "Isoprenoid (Phosphinylmethyl)phosphonates as Inhibitors of Squalene Synthetase", Journal of Medicinal Chemistry, Vol. 31, No. 10, pp. 1869-1871 (1988)
	4AT	Biller, S.A. et al., "Squalene Synthase Inhibitors", Current Pharmaceutical Design, Vol. 2, No. 1, pp. 1-40 (1996)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
LA0093 NP
APPLICATION NO.
10/712,823
APPLICANT
SHER ET AL.
FILING DATE
NOVEMBER 13, 2003
Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	5AA	5,849,918	12/15/98	Esser et al.			
	5AB	5,885,983	3/23/99	Biller et al.			
	5AC	5,962,440	10/5/99	Sulsky			
	5AD	6,017,926	1/25/00	Askew et al.			
	5AE	6,043,265	3/28/00	Murugesan et al.			
	5AF	6,107,329	8/22/00	Hoover et al.			
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	5AM	WO 97/43268	11/20/97	PCT			☐	☐
	5AN	WO 99/00353	1/7/99	PCT			☐	☐
	5AO	WO 99/26659	6/3/99	PCT			☐	☐
	5AP	WO 99/38501	8/5/99	PCT			☐	☐
	5AQ	WO 99/46272	9/16/99	PCT			☐	☐

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	5AR	Bundgaard, H., Chapter 5: "Design and Application of Prodrugs", A Textbook of Drug Design and Development, Harwood Academic Publishers, publ., Krogsgaard-Larsen, P. et al., eds., pp. 113-191 (1991)
	5AS	Bundgaard, H., ed., Design of Prodrugs, Elsevier Science Publishers B.V., publ. (1985) (table of contents)
	5AT	Caprathe, B.W. et al., "Dopamine Autoreceptor Agonists as Potential Antipsychotics. 3. 6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-*f*]quinolin-2-amine", J. Med. Chem., Vol. 34, No. 9, pp. 2736-2746 (1991)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
LA0093 NP
APPLICATION NO.
10/712,823
APPLICANT
SHER ET AL.
FILING DATE
NOVEMBER 13, 2003
Group

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	6AA	WO 99/61431	12/2/99	PCT			☐	☐
	6AB	WO 99/67278	12/29/99	PCT			☐	☐
	6AC	WO 99/67279	12/29/99	PCT			☐	☐
	6AD	WO 00/01389	1/13/00	PCT			☐	☐
	6AE	WO 00/59506	10/12/00	PCT			☐	☐
	6AF	WO 01/00586	1/4/01	PCT			☐	☐
	6AG	WO 01/21602	3/29/01	PCT			☐	☐
	6AH	WO 01/27128	4/19/01	PCT			☐	☐
	AI						☐	☐
	AJ						☐	☐
	AK						☐	☐
	AL						☐	☐
	AM						☐	☐
	AN						☐	☐
	AO						☐	☐
	AP						☐	☐
	AQ						☐	☐
	AR						☐	☐
	AS						☐	☐
	AT						☐	☐
	AU						☐	☐
	AV						☐	☐
	AW						☐	☐
	AX						☐	☐
	AY						☐	☐
	AZ						☐	☐

EXAMINER **DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
LA0093 NP
APPLICATION NO.
10/712,823
APPLICANT
SHER ET AL.
FILING DATE
NOVEMBER 13, 2003
Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	7AA	Capson, T.L., "Synthesis and Evaluation of Ammonium Analogs of Carbocationic Intermediates in Squalene Biosynthesis", dissertation, Department of Medicinal Chemistry, University of Utah, pp. iv-v, Table of Contents, 16-17, 40-43, 48-51, Summary (June 1987)
	7AB	Carling, R.W. et al., "3-Nitro-3,4-dihydro-2(1*H*)-quinolines. Excitatory Amino Acid Antagonists Acting at Glycine-Site NMDA and (*RS*)-α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors", J. Med. Chem., Vol. 36, No. 22, pp. 3397-3408 (1993)
	7AC	Casimir, J.R. et al., "Efficient Synthesis of (*S*)-4-Phthalimido-1,3,4,5-tetrahydro-8-(2,6-dichlorobenzyloxy)-3-oxo-2*H*-2-benzazepin-2-acetic Acid (Pht-Hba(2,6-Cl_2-Bn)-Gly-OH)", J. Org. Chem. Vol. 65, No. 20, pp. 6487-6492 (2000)
	7AD	Corey, E.J. et al., "Application of Unreactive Analogs of Terpenoid Pyrophosphates to Studies of Multistep Biosynthesis. Demonstration That 'Presqualene Pyrophosphate' Is an Essential Intermediate on the Path to Squalene", J. Am. Chem. Soc., Vol. 98, No. 5, pp. 1291-1293 (1976)
	7AE	Cornicelli, J.A. et al., "15-Lipoxygenase and Its Inhibition: A Novel Therapeutic Target for Vascular Disease", Current Pharmaceutical Design, Vol. 5, No. 1, pp. 11-20 (1999)
	7AF	Davis, A.L. et al., "Preparation and Antimicrobial Properties of the D and L Forms of 3-Amino-3,4-dihydro-1-hydroxycarbostyril", Journal of Medicinal Chemistry, Vol. 15, No. 3, pp. 325-327 (1972)
	7AG	Davis, A.L. et al., "Synthesis of the 3-Methyl and 4-Methyl Derivatives of 3-Amino-3,4-dihydro-1-hydroxycarbostyril and Related Compounds", J. Heterocyclic Chem., Vol. 17, pp. 1405-1408 (1980)
	7AH	Davis, A.L. et al., "The Syntheses and Biological Activities of o-Aminophenylalanine and Related Compounds", Archives of Biochemistry and Biophysics, Vol. 102, pp. 48-51 (1963)
	7AI	DeVita, R.J. et al., "Heterocyclic Analogs of the Benzolactam Nucleus of the Non-Peptidic Growth Hormone Secretagogue L-692,429", Bioorganic & Medicinal Chemistry Letters, Vol. 5, No. 12, pp. 1281-1286 (1995)
	7AJ	El-Subbagh, H.I. et al., "Synthesis and Antitumor Activity of Some New Substituted Quinolin-4-one and 1,7-Naphthyridin-4-one Analogs", Arch. Pharm. Pharm. Med. Chem., Vol. 322, pp. 19-24 (1999)
	7AK	Epsztajn, J. et al., "Applications of Organolithium and Related Reagents in Synthesis. Part 3. A General Study of the Reaction of Lithium Alkyls with Pyridine Ketones", J. Chem. Soc. Perkin Trans. I, pp. 213-219 (1985)
	7AL	Ferraris, D. et al., "Catalytic, Enantioselective Alkylation of α-Imino Esters: The Synthesis of Nonnatural α-Amino Acid Derivatives", J. Am. Chem. Soc., Vol. 124, No. 1, pp. 67-77 (2002)
	7AM	Flynn, G.A. et al., "An Acyliminium Ion Route to Cis and Trans "Anti" Phe-Gly Dipeptide Mimetics", Bioorganic & Medicinal Chemistry Letters, Vol. 1, No. 6, pp. 309-312 (1991)
	7AN	Ford, E.S. et al., "Prevalence of the Metabolic Syndrome Among US Adults", J. Am. Med. Assoc., Vol. 287, No. 3, pp. 356-359 (2002)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
LA0093 NP
APPLICATION NO.
10/712,823
APPLICANT
SHER ET AL.
FILING DATE
NOVEMBER 13, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	8AA	Fu, Y. et al., "Sterically Hindered $C^{\alpha,\alpha}$-Disubstituted α-Amino Acids: Synthesis from α-Nitroacetate and Incorporation into Peptides", J. Org. Chem., Vol. 66, No. 21, pp. 7118-7124 (2001)
	8AB	Fujita, M. et al., "A Novel, Convenient Synthesis of 2-Aryl-3-oxo-3,4-dihydro-2*H*-1,4-benzothiazines", Synthesis, pp. 599-604 (1988)
	8AC	Ghiselli, G., "The Pharmacological Profile of FCE 27677: A Novel ACAT Inhibitor with Potent Hypolipidemic Activity Mediated by Selective Suppression of the Hepatic Secretion of ApoB-100-Containing Lipoprotein", Cardiovascular Drug Reviews, Vol. 16, No. 1, pp. 16-30 (1998)
	8AD	Greene, T.W. et al., Protective Groups in Organic Synthesis, Second Edition, John Wiley & Sons, Inc., publ., pp. ix-x (table of contents) (1991)
	8AE	Hamann, B.C. et al., "Sterically Hindered Chelating Alkyl Phosphines Provide Large Rate Accelerations in Palladium-Catalyzed Amination of Aryl Iodides, Bromides, and Chlorides, and the First Amination of Aryl Tosylates", J. Am. Chem. Soc., Vol. 120, No. 29, pp. 7369-7370 (1998)
	8AF	Hara, S., "Ileal Na^+/bile acid cotransporter inhibitors", Drugs of the Future, Vol. 24, No. 4, pp. 425-430 (1999)
	8AG	Hoover, D.J. et al., "Indole-2-carboxamide Inhibitors of Human Liver Glycogen Phosphorylase", J. Med. Chem., Vol. 41, No. 16, pp. 2934-2938 (1998)
	8AH	Huang, Y. et al., "The Improved Preparation of 7,8-dihydro-quinoline-5(6*H*)-one and 6,7-dihydro-5*H*-1-pyridin-5-one", Synthetic Communications, Vol. 28, No. 7, pp. 1197-1200 (1998)
	8AI	Itoh, K. et al., "Synthesis and Angiotensin Converting Enzyme Inhibitory Activity of 1,5-Benzothiazepine and 1,5-Benzoxazepine Derivatives", Chem. Pharm. Bull., Vol. 34, No. 3, pp. 1128-1147 (1986)
	8AJ	Jackson, R.F.W. et al., "Concise Synthesis of Enantiomerically Pure Phenylalanine, Homophenylalanine, and Bishomophenylalanine Derivatives Using Organozinc Chemistry: NMR Studies of Amino Acid-Derived Organozinc Reagents", J. Org. Chem., Vol. 63, No. 22, pp. 7875-7884 (1998)
	8AK	Jössang-Yanagida, A. et al., "Tetrahydropyridoazepines and Tetrahydropyridoazepinones from the Corresponding Dihydroquinolines", J. Heterocyclic Chem., Vol. 15, pp. 249-251 (1978)
	8AL	Kikelj, D. et al., "A Convenient Synthesis of 3,4-Dihydro-2-methyl-3-oxo-2*H*-1,4-benzoxazine-2-carboxylic Acids and 3,4-Dihydro-2-methyl-3-oxo-2*H*-pyrido[3,2-*b*]-1,4-oxazine-2-carboxylic Acid", J. Heterocyclic Chem., Vol. 30, pp. 597-602 (1993)
	8AM	Kluge, M. et al., "Syntheses for 2-Amino and 2-Mercapto-2*H*-1,4-benzoxazin-3(4*H*)-one and 2*H*-1,4-Benzothiazin-3(4*H*)-one as Aza and Thio Analogues of the Natural Product *Blepharigenin*", J. Heterocyclic Chem.,Vol. 33, pp. 1623-1626 (1996)
	8AN	Krause, B.R. et al., Chapter 6: "ACAT Inhibitors: Physiologic Mechanisms for Hypolipidemic and Anti-Atherosclerotic Activities in Experimental Animals", Inflammation: Mediators Pathways, CRC Press Inc., publ., Ruffolo, Jr., R.R. et al., eds., pp. 173-198 (1995)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
LA0093 NP
APPLICATION NO.
10/712,823
APPLICANT
SHER ET AL.
FILING DATE
NOVEMBER 13, 2003
Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	9AA	Lardenois, P. et al., "A Convenient Synthesis of 7,8-dihydroisoquinolin-5(6*H*)-one", Synthetic Communications, Vol. 26, No. 12, pp. 2305-2308 (1996)
	9AB	Larock, R.C., Comprehensive Organic Transformations: A Guide to Functional Group Preparations, VCH Publishers, Inc., publ., pp. xiii-xxviii (table of contents) (1989)
	9AC	Lowe, III, J.A. et al., "5-Phenyl-3-ureidobenzazepin-2-ones as Cholecystokinin-B Receptor Antagonists", J. Med. Chem., Vol. 37, No. 22, pp. 3789-3811 (1994)
	9AD	Martin, W.H. et al., "Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose *in vivo*", Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 1776-1781 (1998)
	9AE	McCord, T.J. et al., "The Synthesis, Configuration, and Conformation of *cis*- and *trans*-3-Amino-3,4-dihydro-1-hydroxy-4-methylcarbostyrils and Other Configurationally Related Compounds", J. Heterocyclic Chem., Vol. 18, pp. 1035-1039 (1981)
	9AF	Morton, G.C. et al., "Novel solid-phase synthesis of 1,5-benzothiazepine-4-one derivatives", Tetrahedron Letters, Vol. 41, pp. 3029-3033 (2000)
	9AG	Murakami, K. et al., "A Novel Insulin Sensitizer Acts as a Coligand for Peroxisome Proliferator-Activated Receptor-α (PPAR-α) and PPAR-γ: Effect of PPAR-α Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats", Diabetes, Vol. 47, pp. 1841-1847 (1998)
	9AH	Murakami, Y. et al., "1,3-Disubstituted Benzazepines as Novel, Potent, Selective Neuropeptide Y Y1 Receptor Antagonists", J. Med. Chem., Vol. 42, No. 14, pp. 2621-2632 (1999)
	9AI	Neumeyer, J.L. et al., "Aporphines. 21. Dopaminergic Activity of Aporphine and Benzylisoquinoline Derivatives. Synthesis of 8-Hydroxyaporphines and 1-(Hydroxybenzyl)-2-*n*-propyl-1,2,3,4-tetrahydroisoquinolines", Journal of Medicinal Chemistry, Vol. 20, No. 2, pp. 190-196 (1977)
	9AJ	Nicolosi, R.J. et al., "The ACAT Inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters", Atherosclerosis, Vol. 137, pp. 77-85 (1998)
	9AK	Ortiz de Montellano, P.R. et al., "Inhibition of Squalene Synthetase by Farnesyl Pyrophosphate Analogues", Journal of Medicinal Chemistry, Vol. 20, No. 2, pp. 243-249 (1977)
	9AL	Parsons, W.H. et al., "Benzolactams. A New Class of Converting Enzyme Inhibitors", Biochemical and Biophysical Research Communications, Vol. 117, No. 1, pp. 108-113 (1983)
	9AM	Rabi-Barakay, A. et al., "Intramolecular Amidoalkylation of Aromatics III. Synthesis of Conformationally Restricted Bridged Peptide Analogues of Phe-Gly", Tetrahedron, Vol. 50, No. 36, pp. 10771-10782 (1994)
	9AN	Robl, J.A. et al., "Dual Metalloprotease Inhibitors. I. Constrained Peptidomimetics of Mercaptoacyl Dipeptides", Bioorganic & Medicinal Chemistry Letters, Vol. 4, No. 15, pp. 1789-1794 (1994)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
LA0093 NP
APPLICATION NO.
10/712,823
APPLICANT
SHER ET AL.
FILING DATE
NOVEMBER 13, 2003
Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	10AA	Rosenblum, S.B. et al., "Discovery of 1-(4-Fluorophenyl)-(3*R*)-[3-(4-fluorophenyl)-(3*S*)-hydroxypropyl]-(4*S*)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption", J. Med. Chem., Vol. 41, No. 6, pp. 973-980 (1998)
	10AB	Saari, W.S. et al., "Synthesis and Evaluation of 2-Pyridinone Derivatives as HIV-1-Specific Reverse Transcriptase Inhibitors. 2. Analogues of 3-Aminopyridin-2(1*H*)-one", J. Med. Chem., Vol. 35, No. 21, pp. 3792-3802 (1992)
	10AC	Salisbury, B.G. et al., "Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461", Atherosclerosis, Vol. 115, pp. 45-63 (1995)
	10AD	Schoen, W.R. et al., "A Novel 3-Substituted Benzazepinone Growth Hormone Secretagogue (L-692,429)", Vol. 37, No. 7, pp. 897-906 (1994)
	10AE	Sendobry, S.M. et al., "Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties", British Journal of Pharmacology, Vol. 120, pp. 1199-1206 (1997)
	10AF	Sicker, D. et al., "A Convenient Synthesis of Heterocyclic *N*-Hydroxylactams", Synthesis, pp. 331-333 (1985)
	10AG	Sicker, D. et al., "Syntheses for 2-Hydroxy-2*H*-1,4-benzothiazin-3(4*H*)-one Derivatives as Thio Analogues of Natural Hemiacetals", J. Heterocyclic Chem., Vol. 31, pp. 809-812 (1994)
	10AH	Slade, J. et al., "Angiotensin Converting Enzyme Inhibitors: 1,5-Benzothiazepine Derivatives", J. Med. Chem., Vol. 28, No. 10, pp. 1517-1521 (1985)
	10AI	Sliskovic, D.R. et al., "ACAT Inhibitors: Potential Anti-atherosclerotic Agents", Current Medicinal Chemistry, Vol. 1, No. 3, pp. 204-225 (1994)
	10AJ	Smith, C. et al., "RP 73163: A Bioavailable Alkylsulphinyl-Diphenylimidazole ACAT Inhibitor", Bioorganic & Medicinal Chemistry Letters", Vol. 6, No. 1, pp. 47-50 (1996)
	10AK	Stout, D.M., "Inhibitors of Acyl-CoA:Cholesterol *O*-Acyl Transferase (ACAT) as Hypocholesterolemic Agents. 6. The First Water-Soluble ACAT Inhibitor with Lipid-Regulating Activity, etc.", Chemtracts-Organic Chemistry, Vol. 8, pp. 359-362 (1995)
	10AL	Tamura, S.Y. et al., "Novel Benzo-Fused Lactam Scaffolds as Factor Xa Inhibitors", Bioorganic & Medicinal Chemistry Letters, Vol. 9, pp. 2573-2578 (1999)
	10AM	Tietze, L.F. et al., "First Synthesis and Structural Determination of Blepharin and 1'-Epiblepharin", Synthesis, pp. 1118-1120 (1991)
	10AN	Turconi, M. et al., "Synthesis, Absolute Configuration, Conformational Analysis and Binding Affinity Properties of Enantiomeric Forms of DAU 5750, a Novel M1-M3 Muscarinic Receptor Antagonist", Bioorganic & Medicinal Chemistry Letters, Vol. 2, No. 12, pp. 1375-1383 (1994)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
LA0093 NP
APPLICATION NO.
10/712,823
APPLICANT
SHER ET AL.
FILING DATE
NOVEMBER 13, 2003
Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	11AA	van Niel, M.B. et al., "CCK_B Selective Receptor Ligands: Novel 1,3,5-trisubstituted benzazepin-2-ones", Bioorganic & Medicinal Chemistry Letters, Vol. 5, No. 13, pp. 1421-1426 (1995)
	11AB	Watthey, J.W.H. et al., "Synthesis and Biological Properties of (Carboxyalkyl)amino-Substituted Bicyclic Lactam Inhibitors of Angiotensin Converting Enzyme", J. Med. Chem., Vol. 28, No. 10, pp. 1511-1516 (1985)
	11AC	Wermuth, C.G. et al., Chapter 31: "Designing Prodrugs and Bioprecursors I: Carrier Prodrugs", The Practice of Medicinal Chemistry, Academic Press, publ., Wermuth, C.G., ed., pp. 671-696 (1996)
	11AD	Worley, J.W. et al., "2-Dialkylphosphonyl- and 2-Alkylidene-3,4-dihydro-3-oxo-2*H*-1,4-benzothiazines", J. Org. Chem., Vol. 40, No. 12, pp. 1731-1734 (1975)
	11AE	Yamada, M. et al., "A Potent Dipeptide Inhibitor of Dipeptidyl Peptidase IV", Bioorganic & Medicinal Chemistry Letters, Vol. 8, pp. 1537-1540 (1998)
	AF	
	AG	
	AH	
	AI	
	AJ	
	AK	
	AL	
	AM	
	AN	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.